Cargando…

Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod

Detalles Bibliográficos
Autores principales:	Mallucci, Giulia, Zito, Antonio, Fabbro, Beatrice Dal, Bergamaschi, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369008/ https://www.ncbi.nlm.nih.gov/pubmed/32711296 http://dx.doi.org/10.1016/j.msard.2020.102414

Ejemplares similares

Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients
por: Mallucci, Giulia, et al.
Publicado: (2021)

Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis
por: Pinki,, et al.
Publicado: (2011)

CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis
por: Schiavetti, Irene, et al.
Publicado: (2023)

Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis
por: Türkoğlu, Recai, et al.
Publicado: (2022)

Disseminated Histoplasmosis in a Patient With Multiple Sclerosis Treated With Fingolimod
por: Abrahamowicz, Aleksandra A., et al.
Publicado: (2021)

Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod
por: Murgia, Federica, et al.
Publicado: (2023)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Non-traumatic Acute Epidural Hematoma in Multiple Sclerosis Treated With Fingolimod
por: Fukai, Ryoko, et al.
Publicado: (2019)

COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
por: Barzegar, Mahdi, et al.
Publicado: (2020)

Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience
por: S., Guerrieri, et al.
Publicado: (2021)

Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod
por: Capuano, Rocco, et al.
Publicado: (2022)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

The economic impact of comorbidity in multiple sclerosis
por: Ponzio, Michela, et al.
Publicado: (2022)

A concise synthesis of Fingolimod: an orally available drug for treating multiple sclerosis
por: Yan, Ning, et al.
Publicado: (2015)

Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis
por: Cohan, Stanley, et al.
Publicado: (2015)

Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
por: Alvarez‐Gonzalez, Cesar, et al.
Publicado: (2017)

Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
por: Foerch, Christian, et al.
Publicado: (2020)

Assessment of Macular Function by Multifocal Electroretinogram in Patients with Multiple Sclerosis Treated with Fingolimod
por: Barbano, Lucilla, et al.
Publicado: (2021)

Serology results after COVID vaccine in multiple sclerosis patients treated with fingolimod
por: Ciccone, A., et al.
Publicado: (2023)

Natural History of Asymptomatic SARS-CoV-2 Infection
por: Sakurai, Aki, et al.
Publicado: (2020)

Challenges of managing the asymptomatic carriers of SARS-CoV-2
por: Rahimi, Farid, et al.
Publicado: (2020)

Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab
por: Iannetta, Marco, et al.
Publicado: (2020)

Effects of Combined Endurance and Resistance Training in Women With Multiple Sclerosis: A Randomized Controlled Study
por: Correale, Luca, et al.
Publicado: (2021)

Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies
por: Maglione, Alessandro, et al.
Publicado: (2022)

Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience
por: Vollmer, Brandi, et al.
Publicado: (2017)

Pooling of samples for testing for SARS-CoV-2 in asymptomatic people
por: Lohse, Stefan, et al.
Publicado: (2020)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Myeloid cells as target of fingolimod action in multiple sclerosis
por: Di Dario, Marco, et al.
Publicado: (2015)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis
por: Ohtani, Ryohei, et al.
Publicado: (2018)

Fingolimod-Associated Macular Edema in the Treatment of Multiple Sclerosis
por: Khan, Asma A, et al.
Publicado: (2023)

Disseminated Cryptococcosis in a 63-year-old Patient with Multiple Sclerosis Treated with Fingolimod
por: Seto, Hiroyuki, et al.
Publicado: (2016)

Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide
por: Bollo, Luca, et al.
Publicado: (2020)

Atypical molluscum contagiosum on multiple sclerosis patients treated with fingolimod: A case report
por: Cheraghmakani, Hamed, et al.
Publicado: (2022)

PM(2.5) exposure as a risk factor for multiple sclerosis. An ecological study with a Bayesian mapping approach
por: Bergamaschi, Roberto, et al.
Publicado: (2020)

Circulating endothelial progenitor cells during pregnancy in multiple sclerosis
por: Mallucci, Giulia, et al.
Publicado: (2020)

Asymptomatic cases in a family cluster with SARS-CoV-2 infection
por: Pan, Xingfei, et al.
Publicado: (2020)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Sudden Death Is More Likely to Result From SARS-COV-2 Infection Than Multiple Sclerosis
por: Finsterer, Josef
Publicado: (2023)

Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies
por: Wallach, Asya I., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lcni8b1pr9bf6unv5524rng3l5